Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT ID: NCT00280059
Last Updated: 2021-01-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
660 participants
INTERVENTIONAL
2006-08-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
NCT00524030
Clinical Study With Lyrica In Patients Suffering From Epilepsy
NCT00922987
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
NCT00596466
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
NCT00684424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Pregabalin
dose 150-600 mg/day given BID
2
Lamotrigine
dose 100-500 mg/day given BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
dose 150-600 mg/day given BID
Lamotrigine
dose 100-500 mg/day given BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Primary generalized seizures.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Bruges, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Plovdiv, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Varna, , Bulgaria
Pfizer Investigational Site
Xi’an, Shanxi, China
Pfizer Investigational Site
Cheng Du Si Chaun, , China
Pfizer Investigational Site
Chongqing, , China
Pfizer Investigational Site
Tianjin, , China
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca Department, Colombia
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Hradec Králové, , Czechia
Pfizer Investigational Site
Ostrava, , Czechia
Pfizer Investigational Site
Pelhřimov, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Rychnov nad Kněžnou, , Czechia
Pfizer Investigational Site
Zlín, , Czechia
Pfizer Investigational Site
Tallinn, , Estonia
Pfizer Investigational Site
Tartu, , Estonia
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Nancy, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bonn, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Ulm, , Germany
Pfizer Investigational Site
Ulm, , Germany
Pfizer Investigational Site
Hong Kong, , Hong Kong
Pfizer Investigational Site
Kowloon, , Hong Kong
Pfizer Investigational Site
Shatin, , Hong Kong
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Győr, , Hungary
Pfizer Investigational Site
Nyíregyháza, , Hungary
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Indore, Madhya Pradesh, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Bangalore, , India
Pfizer Investigational Site
Lucknow, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
Tallaght, Dublin, Ireland
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Foggia, , Italy
Pfizer Investigational Site
Pisa, , Italy
Pfizer Investigational Site
Riga, , Latvia
Pfizer Investigational Site
Riga, , Latvia
Pfizer Investigational Site
Kaunas, , Lithuania
Pfizer Investigational Site
Vilnius, , Lithuania
Pfizer Investigational Site
Vilnius, , Lithuania
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
San Luis Potosí City, , Mexico
Pfizer Investigational Site
The Hague, South Holland, Netherlands
Pfizer Investigational Site
Lillehammer, , Norway
Pfizer Investigational Site
Trondheim, , Norway
Pfizer Investigational Site
Amadora, , Portugal
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Cluj-Napoca, Jud. Cluj, Romania
Pfizer Investigational Site
Bucharest, , Romania
Pfizer Investigational Site
Bucharest, , Romania
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Žilina, , Slovakia
Pfizer Investigational Site
Daejeon, , South Korea
Pfizer Investigational Site
Gwangju, , South Korea
Pfizer Investigational Site
Incheon, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Badalona, Barcelona, Spain
Pfizer Investigational Site
Girona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Linköping, , Sweden
Pfizer Investigational Site
Uppsala, , Sweden
Pfizer Investigational Site
Tainan City, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Rajthevee, Bangkok, Thailand
Pfizer Investigational Site
Muang, Changwat Khon Kaen, Thailand
Pfizer Investigational Site
Bangkok, , Thailand
Pfizer Investigational Site
Stoke-on-Trent, Staffordshire, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Liverpool, , United Kingdom
Pfizer Investigational Site
Treliske, Truro, Cornwall, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kwan P, Brodie MJ, Kalviainen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011 Oct;10(10):881-90. doi: 10.1016/S1474-4422(11)70154-5. Epub 2011 Aug 31.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.